Intellectual Property

At Sterlington, we recognize that intellectual property (IP) is not just a legal concept — it is the lifeblood of innovation, R&D, and business success.

Our IP practice offers integrated advice on all aspects of the protection, enforcement, and exploitation of IP, including patents, trade secrets, and trademarks. We represent individuals and corporations, small or large, in their most important IP matters, from providing strategic advice on how to protect their valuable inventions to bet-the-company litigation. Our IP experience spans a variety of industries, including biotechnology, blockchain, chemicals, consumer products, diagnostic kits, financial services, medical devices, and pharmaceuticals.

Our IP trial lawyers have extensive experience representing innovator pharmaceutical companies in patent litigation against generic manufacturers under the Hatch-Waxman Act, as well as advising biologic manufacturers under the Biologics Price Competition and Innovation Act. We also have significant experience in post-grant patent proceedings before the U.S. Patent and Trademark Office, as well as coordinating parallel patent proceedings abroad.

In addition, our IP team supports our deal teams on the IP and technology aspects of mergers, acquisitions, joint ventures, licenses, spinouts, financings, and other corporate transactions.

Example Matters

$1.25b settlement

Achieved $1.25b settlement for Forward Pharma in global patent dispute with Biogen

IP Dispute

Advised Japanese corporation on scope of damages in IP infringement dispute

Hatch- Waxman patent litigation

Representing Ipsen in Hatch-Waxman patent litigation on its ONIVYDE pancreatic cancer treatment

Biologic dispute favorable settlement

For Sanofi/Regeneron in declaratory judgment patent suit against Genentech relating to EYLEA

Injunction win

Obtained injunction for Merck after Hatch-Waxman trial on patent relating to its CANCIDAS antifungal drug